Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz

Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Jackson ImmunoResearch launches new antibodies and conjugates

GFP is a common fusion protein tag that enables protein expression to be monitored, quantified, and localized within the complex environment of the cell

JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill

The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation

Azenta obtains regulatory approval for clinical long-read whole genome sequencing test

Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics

Strides Pharma Science appoints Dr. C. Muthulingam as Executive VP - R&D

Dr. Muthu was last associated with Mankind Pharma

Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI

Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion